- Home
- IHS vs IMVT Comparison
IHS vs IMVT Comparison
Compare IHS & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHS
- IMVT
- Stock Information
- Founded
- IHS 2001
- IMVT 2018
- Country
- IHS United Kingdom
- IMVT United States
- Employees
- IHS N/A
- IMVT N/A
- Industry
- IHS Telecommunications Equipment
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IHS Telecommunications
- IMVT Health Care
- Exchange
- IHS Nasdaq
- IMVT Nasdaq
- Market Cap
- IHS 2.3B
- IMVT 2.7B
- IPO Year
- IHS 2021
- IMVT N/A
- Fundamental
- Price
- IHS $6.78
- IMVT $16.00
- Analyst Decision
- IHS Strong Buy
- IMVT Buy
- Analyst Count
- IHS 7
- IMVT 10
- Target Price
- IHS $10.18
- IMVT $33.38
- AVG Volume (30 Days)
- IHS 483.9K
- IMVT 1.7M
- Earning Date
- IHS 11-11-2025
- IMVT 11-06-2025
- Dividend Yield
- IHS N/A
- IMVT N/A
- EPS Growth
- IHS N/A
- IMVT N/A
- EPS
- IHS 0.33
- IMVT N/A
- Revenue
- IHS $1,731,025,000.00
- IMVT N/A
- Revenue This Year
- IHS $1.97
- IMVT N/A
- Revenue Next Year
- IHS $5.50
- IMVT N/A
- P/E Ratio
- IHS $20.44
- IMVT N/A
- Revenue Growth
- IHS N/A
- IMVT N/A
- 52 Week Low
- IHS $2.44
- IMVT $12.72
- 52 Week High
- IHS $7.66
- IMVT $32.10
- Technical
- Relative Strength Index (RSI)
- IHS 47.71
- IMVT 50.79
- Support Level
- IHS $6.66
- IMVT $15.81
- Resistance Level
- IHS $6.85
- IMVT $17.15
- Average True Range (ATR)
- IHS 0.19
- IMVT 0.73
- MACD
- IHS -0.03
- IMVT 0.10
- Stochastic Oscillator
- IHS 43.75
- IMVT 57.98
About IHS IHS Holding Limited
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, the Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.